凯信远达上涨5.07%，报2.28美元/股，总市值3532.33万美元

Core Viewpoint - CASI Pharmaceuticals (凯信远达) has shown a significant increase in stock price and revenue growth, while still facing challenges with net profit losses [1] Financial Performance - As of March 31, 2025, CASI reported total revenue of $6.24 million, representing a year-over-year increase of 83.04% [1] - The company recorded a net loss attributable to shareholders of $10.75 million, which is a decrease of 12.83% compared to the previous year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focusing on advanced treatment solutions for blood cancers in Chinese patients [1] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [1] - CASI's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [1]